Wearable Injectors Market Report 2025

The wearable injectors market size has grown rapidly in recent years. It will grow from $8.84 billion in 2024 to $9.91 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to chronic disease management, patient convenience, technological advancements, aging population.

The wearable injectors market size is expected to see rapid growth in the next few years. It will grow to $17.45 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to personalized medicine, remote patient monitoring, drug development, chronic disease management. Major trends in the forecast period include biologics and large molecules, dual-chamber wearables, connected and smart devices, patch pump technology.

The rise in the prevalence of chronic conditions such as diabetes, cardiovascular diseases, and cancers has significantly contributed to the growth of the wearable injectors market. For example, in April 2023, a report from the British Diabetic Association, a UK-based charity supporting individuals with diabetes, highlighted that approximately 4.3 million people in the UK are diagnosed with diabetes. Of these, around 90% have type 2 diabetes, about 8% are diagnosed with type 1 diabetes, and the remaining 2% have other forms of diabetes. The increasing number of patients with diabetes and other chronic conditions has led to a greater demand for treatment solutions, driving the expansion of the wearable injectors market.

The increasing elderly population is expected to be a driving force behind the growth of the wearable injectors market in the future. This demographic consists of older adults, typically aged 65 and above, and wearable injectors offer them a convenient way to self-administer medications, fostering independence and adherence to treatment regimens while reducing the necessity for frequent hospital visits. For example, in October 2022, the World Health Organization reported that globally, one in six individuals would be 60 years old or older by 2030, and it is projected that there will be 2.1 billion elderly individuals by 2050. Hence, the growing geriatric population is a key driver of the wearable injectors market's expansion.

Many companies in the wearable injectors manufacturing market are focusing on developing advanced products such as on-body injectors (OBI) to enhance patient convenience, improve adherence to prescribed treatments, and meet the rising demand for self-administration of biologics. An On-Body Injector (OBI) is a wearable drug delivery device designed to administer medications subcutaneously over a specific period, providing convenience for patients who require large-volume or timed-dose injections. For example, in February 2024, Coherus BioSciences Inc., a US-based biotechnology company, launched UDENYCA, an advanced drug delivery device using the LTS Sorrel wearable platform. This device is designed to administer pegfilgrastim-cbqv, a biosimilar of pegfilgrastim, used the day after chemotherapy to reduce the risk of febrile neutropenia, a condition marked by fever and low white blood cell count due to infections. The OBI ensures precise dosing and convenience by enabling at-home administration, removing the need for additional clinic visits.

Major players in the wearable injectors market are increasingly focusing on introducing innovative medication delivery devices like the enFuse injector to enhance their revenue in the market. The enFuse injector is designed for the self-administration of high-volume drugs, offering patients comfort and convenience. For instance, in September 2023, Enable Injections, Inc., a US-based medical technology company, obtained approval from the US Food and Drug Administration (FDA) for the enFuse injector. This wearable injector is intended for the subcutaneous delivery of EMPAVELI, a medication used by adults with paroxysmal nocturnal hemoglobinuria (PNH) and marketed in the United States by Apellis Pharmaceuticals Inc. The enFuse injector is a compact, wearable device that simplifies the self-administration process with minimal disruption to patients' daily routines. It enables hands-free delivery of up to 25 mL, making it suitable for use at home or in clinical settings. The FDA approval of the enFuse injector provides patients with a more convenient way to administer their medication.

In June 2023, LTS LOHMANN Therapie-Systeme AG, a pharmaceutical company based in Germany, purchased the Sorrel wearable injection device business from Eitan Medical for an undisclosed sum. This acquisition is anticipated to broaden LTS LOHMANN Therapie-Systeme AG's range of drug delivery platforms and enhance its offerings in the areas of large molecules and biologics. Eitan Medical Ltd. is an Israeli medical device company known for its development of innovative drug delivery solutions, including wearable injectors.

Wearable injectors are specialized drug delivery devices that affix to the patient's body during the subcutaneous administration of drugs over a predetermined duration.

These wearable injectors come in two primary types are on-body injectors and off-body injectors. On-body injectors are drug delivery devices attached directly to the patient's skin, typically on the abdomen or the back of the patient's arm. They find applications in various medical fields, including immuno-oncology, diabetes, cardiovascular diseases, among others, and are employed across a range of healthcare settings, including hospitals, clinics, and home care.

The wearable injectors market research report is one of a series of new reports that provides wearable injectors market statistics, including wearable injectors industry global market size, regional shares, competitors with a wearable injectors market share, detailed wearable injectors market segments, market trends and opportunities, and any further data you may need to thrive in the wearable injectors industry. This wearable injectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the wearable injectors market include Amgen Inc., Becton Dickinson and Company (BD), Enable Injections LLC, Insulet Corporation, Ypsomed Holding AG, Medtronic MiniMed Inc., Tandem Diabetes Care Inc., Valeritas Inc., West Pharmaceutical Services Inc., Sensile Medical AG, Gerresheimer AG, Dexcom Inc., Consort Medical PLC, United Therapeutics Corporation, Bühler Motor GmbH, Debiotech SA, Cellnovo Group, EoFlow Co. Ltd., CeQur SA, Haselmeier AG, Johnson & Johnson, kaleo Inc., Mylan N.V., Nemera Development S.A., F. Hoffmann-La Roche Ltd., Zosano Pharma Corporation.

North America was the largest region in the wearable injectors market in 2024. Western Europe was the second-largest region in the wearable injectors market analysis. The regions covered in the wearable injectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the wearable injectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The wearable injectors market consists of sales of instruments such as on-body injectors and off-body injectors. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.